Innate Pharma S.A. ADS
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
Open IPHA dashboard ↗Pluri Inc. Common Stock
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. The company's product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. It also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products. The company operates in the field of regenerative medicine, food tech, immunotherapy, CDMO, and AgTech. It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Open PLUR dashboard ↗